Bristol-Myers, Sanofi Sued by Hawaii Over Plavix Labeling

The clinical access to individuals' protected genetic information as it relates to dosage regimens is pertinent. Seen here in the 2014 case of the State of Hawaii's legal battle over Plavix, the clinical utility of pharmacogenomics is plainly seen. Hawaii Attorney General David Louie, in an emailed statement, noted that, "38 to 79 percent of Pacific-Islanders and 40 to 50 percent of East Asians may respond poorly to Plavix because of a genetic predisposition to inadequately metabolize the drug,", which the state felt was inappropriately accounted for by Bristol-Myers and Sanofi, their $100 million profit from Plavix sales from 1998 to 2010 being the reason for the suit. 

Read Article Here

 Bristol - Myers, Sanofi Sued by Hawaii Over Plavix Labeling via Bloomberg Business 

Bristol - Myers, Sanofi Sued by Hawaii Over Plavix Labeling via Bloomberg Business